The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.
JJ Feld, D Colledge, V Sozzi, R Edwards, M Littlejohn, SA Locarnini
Antiviral Research | Published : 2007
Nucleos(t)ide analogue antiviral therapy for chronic hepatitis B has proven to be effective in the short term but the frequent development of resistance limits its clinical utility. Agents targeting other stages of viral replication are needed in order to develop improved combination therapies. The phenylpropenamide derivatives AT-61 and AT-130 have been shown to inhibit HBV replication in vitro, but the mechanism of action of these compounds remains undefined. The aim of this study was to determine the mechanism of action of AT-130, a non-nucleoside inhibitor of HBV in several in vitro models of replication. These studies found that AT-130 inhibited HBV DNA replication in hepatoma cells but..View full abstract